В. М. Мицура, Е. В. Воропаев, С. В. Жаворонок, О. В. Осипкина, Д. В. Терешков
УО «Гомельский государственный медицинский университет», УО «Белорусский государственный медицинский университет», УЗ «Гомельская областная инфекционная клиническая больница»
Обследовано 237 пациентов с хроническим гепатитом С (ХГС) (63% мужчины; 57% с генотипом 1 вируса) в Гомеле и Минске.
ключевые слова: полиморфизм гена ИЛ-28В, хронический гепатит С, интерферонотерапия
Distribution and prognostic value of two interleukin-28b gene polymorphisms to evaluate the effectiveness of antiviral treatment of chronic hepatitis C
V. M. Mitsura, E. V. Voropaev, S. V. Zhavoronok, O. V. Osipkina, D. V. Tereshkov
The study involved 237 patients with chronic hepatitis C (CHC) (63% men, 57% with hepatitis C virus (HCV) genotype 1) in Gomel and Minsk. Single nucleotide polymorphisms (SNP) of the gene IL28B 39743165T>G (rs8099917) and SNP 39738787C> T (rs12979860) were determined by polymerase chain reaction. «Favorable» SNP allelic variants of IL28B gene in patients with CHC were less common vs. European population. In patients with HCV genotype 1, mutant alleles in both SNPs were more common vs. those with other genotypes. Both SNPs are good predictors of antiviral treatment effectiveness in patients with genotype 1 HCV. In those with genotype 1 HCV the SNPs effectively predict response to therapy for both IFN + RBV schemes and schemes for PEG-IFN + RBV.
keywords: IL28B gene polymorphism, chronic hepatitis C, interferon therapy
1. Влияние генетических полиморфизмов гена IL28B на эффективность противовирусной терапии хронического гепатита С стандартным интерфероном-α / А. В. Лапшин [и др.] // Росс. журн. гастроэнтерол. – 2013. – Т. 23, № 1. – С. 23–29.
2. EASL Clinical Practice Guidelines: Management of hepatitis C vir us infection // J. Hepatol. – 2011. – Vol. 55. – P. 245–264.
3. Genetic vari ation in IL28B and spontaneous clearance of hepatitis C vir us / D. L. Thomas [et al.] // Nature. – 2009. – Vol. 461. – P. 798–801.
4. Genetic vari ation in IL28B predicts hepatitis C treatment-induced vir al clearance / D. Ge [et al.] // Nature. – 2009. – Vol. 461. – P. 399–401.
5. Hepatitis, C pharmacogenetics: State of the art in / N. H. Afdhal [et al.] // Hepatology. – 2011. – Vol. 53, № 1. – P. 336–345.
6. Interleukin-28B polymorphi sm improves viral kinetics and is the strongest pretreatment predictor of sustained vir ologic response in genotype 1 hepatitis C vir us / A. J. Thompson [et al.] // Gastroenterology. – 2010. – Vol. 139. – P. 120–129.
7. Slev, P. Host genomics and HCV personalized medicine / P. Slev // Ann. Clin. Lab. Sci. – 2012. – Vol. 42, № 4. – P. 363–369.
Формат файла: pdf (159.44 Кб)